|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kopczyńska E: Role of microRNAs in the
resistance of prostate cancer to docetaxel and paclitaxel. Contemp
Oncol (Pozn). 19:423–427. 2015.PubMed/NCBI
|
|
3
|
Zhang W, Meng Y, Liu N, Wen XF and Yang T:
Insights into chemoresistance of prostate cancer. Int J Biol Sci.
11:1160–1170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karnak D and Xu L: Chemosensitization of
prostate cancer by modulating Bcl-2 family proteins. Curr Drug
Targets. 11:699–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He H, Tian W, Chen H and Deng Y:
MicroRNA-101 sensitizes hepatocellular carcinoma cells to
doxorubicin-induced apoptosis via targeting Mcl-1. Mol Med Rep.
13:1923–1929. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rivankar S: An overview of doxorubicin
formulations in cancer therapy. J Cancer Res Ther. 10:853–858.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Luca P, Vazquez ES, Moiola CP, Zalazar
F, Cotignola J, Gueron G, Gardner K and De Siervi A: BRCA1 loss
induces GADD153-mediated doxorubicin resistance in prostate cancer.
Mol Cancer Res. 9:1078–1090. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carey JP, Knowell AE, Chinaranagari S and
Chaudhary J: Id4 promotes senescence and sensitivity to
doxorubicin-induced apoptosis in DU145 prostate cancer cells.
Anticancer Res. 33:4271–7278. 2013.PubMed/NCBI
|
|
9
|
Lv L, Qiu K, Yu X, Chen C, Qin F, Shi Y,
Ou J, Zhang T, Zhu H, Wu J, et al: Amphiphilic Copolymeric micelles
for doxorubicin and curcumin co-delivery to reverse multidrug
resistance in breast cancer. J Biomed Nanotechnol. 12:973–985.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pan C, Wang X, Shi K, Zheng Y, Li J, Chen
Y, Jin L and Pan Z: MiR-122 reverses the doxorubicin-resistance in
hepatocellular carcinoma cells through regulating the tumor
metabolism. PLoS One. 11:e01520902016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bischoff SC: Quercetin: Potentials in the
prevention and therapy of disease. Curr Opin Clin Nutr Metab Care.
11:733–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Erlund I: Review of the flavonoids
quercetin, hespertin and naringenin. dietary sources,
bioactivities, bioavailability and epidemiology. Nutr Res.
24:851–874. 2004. View Article : Google Scholar
|
|
13
|
Ramos S: Effects of dietary flavonoids on
apoptotic pathways related to cancer chemoprevention. J Nutr
Biochem. 18:427–442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Tang C, Li L, Li R and Fan Y:
Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of
Hsp27 and COX-2 in vitro and in vivo. J Exp Clin Cancer Res.
35:612016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kang Q and Yan S: Piperlongumine reverses
doxorubicin resistance through the PI3K/Akt signaling pathway in
K562/A02 human leukemia cells. Exp Ther Med. 9:1345–1350. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zorov DB, Juhaszova M and Sollott SJ:
Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS
release. Physiol Rev. 94:909–950. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jung KA, Choi BH and Kwak MK: The
c-MET/PI3K signaling is associated with cancer resistance to
doxorubicin and photodynamic therapy by elevating BCRP/ABCG2
expression. Mol Pharmacol. 87:465–476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferracini R, Longati P, Naldini L, Vigna E
and Comoglio PM: Identification of the major autophosphorylation
site of the Met⁄hepatocyte growth factor receptor tyrosine kinase.
J Biol Chem. 266:19558–19564. 1991.PubMed/NCBI
|
|
20
|
Knudsen BS and Vande Woude G: Showering
c-Met dependent cancers with drugs. Curr Opin Genet Dev. 18:87–96.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han Y, Luo Y, Zhao J, Li M and Jiang Y:
Overexpression of c-Met increases the tumor invasion of human
prostate LNCaP cancer cells in vitro and in vivo. Oncol Lett.
8:1618–1624. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yasuda K, Nagakawa O, Akashi T, Fujiuchi
Y, Koizumi K, Komiya A, Saiki I and Fuse H: Serum active hepatocyte
growth factor (AHGF) in benign prostatic disease and prostate
cancer. Prostate. 69:346–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen JT, Huang CY, Chiang YY, Chen WH,
Chiou SH, Chen CY and Chow KC: HGF increases cisplatin resistance
via down-regulation of AIF in lung cancer cells. Am J Respir Cell
Mol Biol. 38:559–565. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Que W and Chen J: Knockdown of c-Met
inhibits cell proliferation and invasion and increases
chemosensitivity to doxorubicin in human multiple myeloma U266
cells in vitro. Mol Med Rep. 4:343–349. 2011.PubMed/NCBI
|
|
25
|
Toschi L and Jänne PA: Single-agent and
combination therapeutic strategies to inhibit hepatocyte growth
factor⁄MET signaling in cancer. Clin Cancer Res. 14:5941–5946.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hung TH, Li YH, Tseng CP, Lan YW, Hsu SC,
Chen YH, Huang TT, Lai HC, Chen CM, Choo KB and Chong KY: Knockdown
of c-MET induced apoptosis in ABCB1-overexpressed
multidrug-resistance cancer cell lines. Cancer Gene Ther.
22:262–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yao Y, Dou C, Lu Z, Zheng X and Liu Q:
MACC1 suppresses cell apoptosis in hepatocellular carcinoma by
targeting the HGF/c-MET/AKT pathway. Cell Physiol Biochem.
35:983–996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trovato M, Torre ML, Ragonese M, Simone A,
Scarfì R, Barresi V, Giuffrè G, Benvenga S, Angileri FF, Tuccari G,
et al: HGF/c-met system targeting PI3K/AKT and
STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an
immunohistochemical characterization in view of targeted therapies.
Endocrine. 44:735–743. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Danielsen SA, Eide PW, Nesbakken A, Guren
T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in
colorectal cancer. Biochim Biophys Acta. 1855:104–121.
2015.PubMed/NCBI
|
|
32
|
Li H, Zeng J and Shen K: PI3K/AKT/mTOR
signaling pathway as a therapeutic target for ovarian cancer. Arch
Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toren P and Zoubeidi A: Targeting the
PI3K/Akt pathway in prostate cancer: Challenges and opportunities
(review). Int J Oncol. 45:1793–1801. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang KD and Ling MT: Targeting
drug-resistant prostate cancer with dual PI3K/mTOR inhibition. Curr
Med Chem. 21:3048–3056. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang F, Song L, Wang H, Wang J, Xu Z and
Xing N: Quercetin in prostate cancer: Chemotherapeutic and
chemopreventive effects, mechanisms and clinical application
potential (Review). Oncol Rep. 33:2659–2668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang P, Henning SM, Magyar CE, Elshimali
Y, Heber D and Vadgama JV: Green tea and quercetin sensitize PC-3
xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin
Cancer Res. 35:732016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jung YH, Heo J, Lee YJ, Kwon TK and Kim
YH: Quercetin enhances TRAIL-induced apoptosis in prostate cancer
cells via increased protein stability of death receptor 5. Life
Sci. 86:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang F, Song L, Wang H, Wang J, Xu Z and
Xing N: Combination of quercetin and 2-Methoxyestradiol enhances
inhibition of human prostate cancer LNCaP and PC-3 cells xenograft
tumor growth. PLoS One. 10:e01282772015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiao D, Wang J, Lu W, Tang X, Chen J, Mou
H and Chen QY: Curcumin inhibited HGF-induced EMT and angiogenesis
through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways
in lung cancer. Mol Ther Oncolytics. 3:160182016. View Article : Google Scholar : PubMed/NCBI
|
